Whalesbook
Gaudium IVF Lists Amid Slowing IPO Market
Gaudium IVF & Women Health Limited began trading on February 27, 2026, following its initial public offering (IPO). The company, which operates over 30 fertility centers across India, raised ₹165 crore through a public sale involving new shares and an offer for existing shares from promoter Dr. Manika Khanna. The IPO was priced at the upper band of ₹79 per share, aiming to fund expansion and strengthen its finances. The listing positions Gaudium IVF as a key player in the public market for India's rapidly expanding fertility care market, a sector attracting significant investor interest due to demographic shifts and improved healthcare access. However, the company's debut occurs as the broader Indian IPO market is slowing, raising questions about how new companies are valued and investor interest.
India's Fertility Market Sees Rapid Growth
India's fertility services market is expected to grow strongly, with forecasts indicating an expansion from USD 0.8 billion in 2022 to over USD 4.6 billion by 2032, at a compound annual growth rate (CAGR) of 18.08%. This expansion is driven by increasing infertility rates, delayed parenthood, lifestyle factors, and greater awareness of assisted reproductive technologies (ART). Gaudium IVF, founded in 2015, has established a significant presence using a hub-and-spoke model, offering services like IVF, ICSI, and reproductive preservation. In FY2025, the company reported an EBITDA margin of 40.48% and a net profit margin of 26.96%, with a significant Return on Equity (ROE) of 41.31%. While its IVF success rates hover around 58%, positioning it competitively against peers like Indira IVF and Apollo Fertility, Gaudium IVF is much smaller than global players like Progyny Inc. Its market capitalization post-IPO was estimated between ₹524 crore and ₹575 crore, with a P/E ratio ranging from 22.3 to 25.36. This valuation reflects confidence in the sector's future, despite scrutiny amid a more cautious market.
Indian IPO Market Cools in Early 2026
Following a record-breaking year in 2025, Indian primary market activity has slowed in early 2026. While 2025 saw 373 mainboard and SME listings raising ₹1.95 trillion, the initial months of 2026 have seen lower subscription rates and reduced investor risk appetite. Global market weakness, foreign investor selling, and profit-taking have led to market corrections, with benchmark indices experiencing sharp declines on March 9, 2026. Recent IPOs have seen weak listing days and low pre-listing premiums, indicating a shift towards focusing more on fundamentals and long-term prospects over pure momentum. This environment presents a challenge for new listings, including Gaudium IVF, requiring companies to show clear profits and solid growth plans.
Key Risks for Gaudium IVF
Despite the promising growth trajectory of the fertility sector, several risks could impact Gaudium IVF. Reliance on its founder and CEO, Dr. Manika Khanna, who is instrumental to its operations and brand identity, is a key person risk. Historically, Dr. Khanna and Gaudium IVF faced a consumer complaint alleging medical negligence and complications arising from infertility treatment, though the party involved denied negligence. The sector is highly competitive, with major players like Indira IVF, Apollo Fertility, and Nova IVF vying for market share. Furthermore, the Assisted Reproductive Technology (Regulation) Act, 2021, and its rules aim to standardize practices but create a complex regulatory environment for clinics, potentially affecting their operations and services. Aggressive expansion plans, including new centers, require substantial investment and carry execution risks. The current cautious market sentiment could also pressure valuations and limit stock upside, especially if broader market corrections continue.
What's Next for Gaudium IVF
India's fertility services market outlook remains strong, supported by ongoing demand and technological advances. Gaudium IVF's expansion and focus on profits aim to secure its share of this expanding market. Near-term performance will depend on its ability to navigate difficult IPO market conditions, manage growth, and deliver consistent results within a competitive and evolving regulatory landscape. Maintaining strong margins and ROE during expansion will be crucial for ongoing investor confidence.